title: Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis.
abstract: OBJECTIVE
  To review current management of neurogenic lower urinary tract dysfunction (NLUTD) in MS patients and give recommendations on the joint role of the neurologist and urologist in NLUTD management.
  
  
  METHODS
  An algorithm for evaluation and referral of MS patients to urologists was created. It is an outcome of discussions about current knowledge, existing guidelines, and key issues during two Belgian consensus meetings attended by neurologists, urologists and other stakeholders involved in MS management. At these meetings, updated information on management of NLUTD in MS was exchanged and the neurologists' opinion on how to integrate this in the other aspects of care in MS patients was explored.
  
  
  RESULTS
  Short evaluation of NLUTD in MS patients by neurologists and appropriate referral to urologists could accelerate proper diagnosis and treatment. Neurologists can play a central role in the inter-disciplinary communication on interactions between disease manifestations of MS and their treatments.
  
  
  CONCLUSIONS
  The coordinating role of neurologists in NLUTD management may considerably improve QoL in MS patients. More research is needed to evaluate outcomes of urological assessments and treatment.
authors.affiliation: Universitair Ziekenhuis Leuven, Leuven, Belgium. Electronic address: dirk.deridder@uzleuven.be.
authors.forename: Dirk
authors.initials: D
authors.lastname: De Ridder
authors.forename: Frank
authors.initials: F
authors.lastname: Van Der Aa
authors.forename: Jan
authors.initials: J
authors.lastname: Debruyne
authors.forename: Marie-Beatrice
authors.initials: MB
authors.lastname: D'hooghe
authors.forename: Benedicte
authors.initials: B
authors.lastname: Dubois
authors.forename: Daniel
authors.initials: D
authors.lastname: Guillaume
authors.forename: Marco
authors.initials: M
authors.lastname: Heerings
authors.forename: Stefan
authors.initials: S
authors.lastname: Ilsbroukx
authors.forename: Robert
authors.initials: R
authors.lastname: Medaer
authors.forename: Guy
authors.initials: G
authors.lastname: Nagels
authors.forename: Pierrette
authors.initials: P
authors.lastname: Seeldrayers
authors.forename: William
authors.initials: W
authors.lastname: Van Landegem
authors.forename: Barbara
authors.initials: B
authors.lastname: Willekens
authors.forename: Anne-Françoise
authors.initials: AF
authors.lastname: Zicot
mesh_terms: D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D032921:Consensus; D020233:Gait Disorders, Neurologic / Q000209:etiology; D017408:Guidelines as Topic; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D009103:Multiple Sclerosis / Q000150:complications*; D009462:Neurology; D009465:Neuromuscular Agents; D010820:Physicians; D015995:Prevalence; D012017:Referral and Consultation; D012307:Risk Factors; D001743:Urinary Bladder / Q000601:surgery; D001750:Urinary Bladder, Neurogenic / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D013520:Urologic Surgical Procedures; D014572:Urology
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A
keywords: Multiple sclerosis; Neurogenic; Neurology; Urinary bladder; Urology